Sellas Life Sciences is trading at $11.69 (up 4.2%) as its recent rebound extends following a strong move in the prior session.

  • Investors remain focused on optimism surrounding the late-stage REGAL trial and continued institutional interest highlighted in recent trading commentary.
  • Broader strength across the biotechnology sector and U.S. equities is providing additional support to market sentiment.